|
A new drug has been recently approved by FDA (Food and Drug Administration) so that you can support bone cancer patients experiencing an advanced phase of the disease by decreasing the risk of bone fracture. Since the same complication is really a symptom in osteoporosis, cancer medication has been extended by an osteoporosis medicine. Xgeva, manufactured by Amgen Inc. got the stamp approval for cancer medication and is expected to considerably reduce fracture-based complications typically associated with metastases.
|
